Given that the antidiabetic action of anakinra mainly relies on the preservation of beta cell mass and function, this drug may be a good therapeutic option to counteract IL-1β-driven beta cell dysfunction and to halt or slow down the progressive decline in insulin secretion occurring over time in RA patients with comorbid T2D and insulin resistance. Here, IL1B is linked to rheumatoid arthritis.